ENTA — ENANTA PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1177648 ·
Last close
$8.69
Market Cap
$253.10M
52W High
$17.15
52W Low
$8.60
ADV30
263,240
Next earnings
2027-02-08

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 14,359,000 — -17,236,000 -19,501,000 296,870,000 33,419,000 195,802,000
Mar 2026 17,159,000 — -11,852,000 -13,091,000 314,704,000 34,928,000 198,117,000
Dec 2025 18,615,000 — -11,253,000 -11,938,000 329,503,000 37,437,000 202,912,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-35,316,000
Investing CF
$-19,055,000
Financing CF
$42,978,000
CapEx
$-1,623,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.41
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-449,459,000
Inventory
—
Receivables
$6,534,000
ST Investments
$156,087,000
EBIT TTM
$-50,215,000
Pretax Income TTM
$-63,131,000
Interest Exp TTM
$12,916,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$65,258,000
EBITDA
$-53,819,000
Free Cash Flow
$-22,656,876
Enterprise Value
$369,999,200
Total Cash
$189,506,000
Total Debt
$182,040,000
Shares Out
29,125,402
Trailing EPS
$-2.42
Book Value
$3.47
ROE
-70.1%
ROA
-12.3%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 65,324,000 -85,349,000 -81,889,000 280,732,000 216,015,000 64,717,000 -19,272,000
Sep 2024 67,635,000 -121,691,000 -116,045,000 376,652,000 247,838,000 128,814,000 -78,764,000
Sep 2023 79,204,000 -137,207,000 -133,816,000 462,275,000 245,540,000 216,735,000 -103,154,000
Sep 2022 86,160,000 -123,844,000 -121,755,000 375,410,000 54,076,000 321,334,000 -84,782,000

TTM Snapshot

Revenues TTM
$65,258,000
NetIncome TTM
$-63,230,000
OpCashFlow TTM
—
Assets (Latest)
$296,870,000
Forward EPS
$-2.35

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $8.23 · call volume: 1 · put volume: 103
Expected Move to 2027-04-16: ±$5.46 (66.40%) — implied range $2.76 – $13.69 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CAMP Camp4 Therapeutics Corp $251.02M $4.00 —
NWBO NORTHWEST BIOTHERAPEUTICS INC $250.73M $0.15 —
PRE Prenetics Global Ltd $248.19M $16.33 —
QTTB Q32 Bio Inc. $258.24M $8.63 —
TTRX Turn Therapeutics Inc. $261.40M $8.55 —

News headlines (Yahoo Finance, 1h cache)

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
2026-11-16 21:10 · Yahoo
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot
2026-11-16 21:08 · Yahoo
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
2026-11-16 21:01 · Yahoo
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-04 12:00 · Yahoo
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
2026-10-28 11:00 · Yahoo
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
2026-10-26 11:00 · Yahoo
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
2026-10-13 11:00 · Yahoo
Enanta Pharmaceuticals to Participate in September Investor Conferences
2026-09-01 11:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
2026-08-10 21:10 · Yahoo
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
2026-08-10 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.